This week, Massachusetts stem cell biotechnology company Asymmetrex was the feature news story by online business and technology news platform Superb Crew. The attraction for the choice of Asymmetrex is the company’s recent announcement of its plan to begin offering free tissue stem cell counting to the stem cell research, stem cell medicine, and pharmaceutical industries.
In its June 22 online post, business and technology news platform Superb Crew reported its feature interview with Dr. James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex. Superb Crew decided to highlight Asymmetrex after the company announced on June 16 that starting July 5 it would begin offering free tissue stem cell counting at its company website.
In the interview, Sherley discussed Asymmetrex’s tissue stem cell counting technology with the perspective that it is a very recent development for the industry. He noted that, like many new transformative biotechnologies, it and its value are not yet widely known. The planned free stem cell counting site is a part of Asymmetrex’s greater vision to increase academic and industry awareness of the need for tissue stem cell counting and its value, while at the same time making it readily available for immediate practice.
An earlier podcast series on “Counting Stem Cells” featured on the international stem cell industry networking platform RegMedNet, relates the many benefits of Asymmetrex’s technology for stem cell research, stem cell medicine, tissue stem cell biomanufacturing, pharmaceutical development, and environmental health science. By getting the technology out into use for free, Asymmetrex plans to “ignite a widespread adoption of tissue stem cell counting as [the] new normal” for tissue stem cell research, stem cell medicine, and drug development.
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dosage and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies, cell biomanufacturing, and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.